MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-02-2026
AngioDynamics Financial Ratios 2011-2026 | ANGO
Annual Financial Ratios AngioDynamics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-10.4 | -1.6 | -6.3 | -33.2 | -28.6 | -4.6 | -66.2 | 50.5 | 118.5 | -11.9 | -179.1 | 185.8 | -641.7 | -59.8 | 43.6 |
P/S |
1.2 | 1.0 | 1.0 | 2.8 | 3.1 | 2.9 | 2.7 | 2.4 | 1.7 | 1.5 | 1.6 | 1.6 | 1.1 | 1.4 | 1.6 |
EPS |
-0.8 | -4.6 | -1.3 | -0.7 | -0.8 | -4.4 | 1.6 | 0.4 | 0.1 | -1.2 | -0.1 | 0.1 | -0.0 | -0.2 | 0.3 |
EV (Enterprise Value) |
396 M | 338 M | 439 M | 981 M | 976 M | 844 M | 732 M | 913 M | 739 M | 707 M | 795 M | 820 M | 636 M | 479 M | 340 M |
EBITDA per Share |
-0.35 | -4.1 | -0.51 | 0.02 | -0.24 | -3.77 | 0.427 | 1.16 | 1.16 | 0.899 | 0.99 | 1.12 | 1.12 | 0.891 | 0.852 |
EV/EBITDA |
-102.0 | 91.0 | 40.1 | 19.6 | 15.1 | 18.7 | 19.9 | 17.8 | 13.2 | 19.1 | 14.8 | ||||
PEG |
0.02 | 0.0 | 0.01 | 0.13 | 0.13 | 0.02 | -0.24 | 0.23 | 1.07 | 0.01 | 0.88 | 0.34 | -7.13 | 0.37 | -1.25 |
P/B |
1.9 | 1.5 | 0.9 | 2.1 | 2.1 | 1.7 | 1.2 | 1.5 | 1.2 | 1.0 | 1.1 | 1.1 | 0.7 | 0.6 | 0.9 |
P/CF |
-35.1 | -10.7 | 4221.4 | -122.5 | 37.4 | -52.2 | 21.5 | 21.9 | 11.3 | 13.1 | 45.2 | 47.5 | 28.1 | 33.9 | 11.4 |
ROE % |
-18.58 | -89.67 | -13.86 | -6.25 | -7.18 | -36.67 | -1.81 | 3.01 | 0.97 | -8.59 | -0.60 | 0.57 | -0.12 | -0.97 | 2.00 |
ROA % |
-12.13 | -58.03 | -9.85 | -4.80 | -5.62 | -28.07 | -1.33 | 2.32 | 0.71 | -6.00 | -0.42 | 0.39 | -0.08 | -0.71 | 1.86 |
ROCE % |
-21.84 | -93.60 | -13.53 | -6.71 | -8.03 | -36.74 | -0.14 | 4.05 | 3.96 | 2.20 | 2.44 | 3.09 | 3.09 | 1.98 | 2.90 |
Current Ratio |
2.9 | 2.8 | 3.5 | 4.3 | 4.6 | 4.3 | 4.3 | 2.9 | 2.2 | 2.2 | 2.5 | 2.1 | 2.2 | 2.9 | 7.6 |
DSO |
54.0 | 57.9 | 56.6 | 50.6 | 41.8 | 51.7 | 61.7 | 44.4 | 51.3 | 56.7 | 59.7 | 64.0 | 53.2 | 84.1 | 45.9 |
DIO |
166.0 | 141.8 | 118.4 | 121.3 | 147.6 | 160.2 | 127.6 | 106.7 | 114.7 | 112.5 | 136.6 | 127.6 | 116.1 | 212.6 | 114.0 |
DPO |
96.2 | 95.6 | 76.0 | 57.8 | 52.7 | 67.2 | 72.7 | 34.4 | 38.1 | 31.7 | 48.0 | 68.8 | 51.7 | 111.2 | 46.2 |
Operating Cycle |
220.0 | 199.7 | 175.0 | 171.9 | 189.4 | 211.9 | 189.3 | 151.1 | 166.0 | 169.2 | 196.3 | 191.6 | 169.3 | 296.7 | 159.9 |
Cash Conversion Cycle |
123.8 | 104.1 | 99.0 | 114.1 | 136.7 | 144.7 | 116.6 | 116.7 | 127.9 | 137.5 | 148.4 | 122.9 | 117.6 | 185.5 | 113.8 |
All numbers in USD currency
Quarterly Financial Ratios AngioDynamics
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.19 | -0.26 | - | -0.11 | -0.26 | -0.31 | - | -4.67 | -0.72 | 1.15 | - | -0.24 | -0.21 | -0.33 | -0.55 | -0.13 | -0.21 | -0.18 | -0.39 | -0.09 | -0.11 | -0.11 | -0.11 | -0.11 | -0.07 | -0.03 | -0.07 | -0.03 | 0.06 | -0.01 | 0.06 | -0.01 | 0.01 | - | 0.01 | - | 0.37 | 0.04 | 0.37 | 0.04 | -0.01 | -0.02 | -0.01 | -0.02 | 0.03 | 0.01 | 0.04 | 0.01 | 0.04 | 0.01 | - | -0.01 | -0.01 | -0.01 | 0.06 | -0.02 | 0.09 | 0.05 | 0.09 | 0.05 |
EBITDA per Share |
-0.25 | -0.11 | - | -0.18 | -0.21 | -0.16 | - | -4.89 | -0.24 | 1.05 | - | -0.11 | -0.08 | -0.14 | -0.15 | -0.01 | -0.1 | -0.03 | -0.06 | 0.01 | -0.01 | 0.04 | 0.21 | 0.04 | 0.03 | 0.12 | 0.2 | 0.12 | 0.05 | -0.01 | 0.43 | 0.16 | 0.14 | 0.16 | 0.35 | 0.16 | 0.54 | 0.27 | 0.76 | 0.27 | 0.14 | 0.2 | 0.44 | 0.23 | 0.21 | 0.25 | 0.52 | 0.28 | 0.16 | 0.21 | 0.39 | 0.21 | 0.26 | 0.21 | 0.5 | 0.12 | 0.25 | 0.23 | 0.4 | 0.23 |
ROE % |
-15.50 | -16.59 | -14.63 | -100.47 | -183.94 | -185.44 | -82.36 | -84.74 | -1.28 | 3.87 | -7.61 | -12.67 | -11.44 | -11.29 | -9.75 | -8.17 | -8.62 | -7.62 | -6.96 | -4.42 | -3.76 | -3.26 | -2.77 | -2.28 | -1.54 | -0.71 | 0.13 | 0.96 | 1.08 | 0.74 | 0.34 | 0.00 | 0.08 | 2.66 | 2.92 | 5.58 | 5.84 | 3.16 | 2.76 | -0.01 | -0.41 | -0.15 | 0.04 | 0.36 | 0.58 | 0.64 | 0.67 | 0.41 | 0.24 | -0.06 | -0.22 | 0.17 | 0.12 | 0.73 | 1.14 | 1.34 | 1.81 | 0.34 | 0.57 | 0.34 |
ROA % |
-10.29 | -10.88 | -9.59 | -67.38 | -123.63 | -125.76 | -54.32 | -56.07 | -0.02 | 4.27 | -5.60 | -9.49 | -8.65 | -8.64 | -7.56 | -6.40 | -6.73 | -5.95 | -5.43 | -3.42 | -2.89 | -2.55 | -2.21 | -1.82 | -1.25 | -0.60 | 0.10 | 0.73 | 0.82 | 0.58 | 0.27 | -0.00 | 0.06 | 1.95 | 2.14 | 3.99 | 4.18 | 2.21 | 1.93 | -0.01 | -0.29 | -0.11 | 0.02 | 0.24 | 0.40 | 0.43 | 0.45 | 0.27 | 0.16 | -0.04 | -0.15 | 0.13 | 0.09 | 0.65 | 1.01 | 1.27 | 1.68 | 0.31 | 0.53 | 0.31 |
ROCE % |
-24.16 | -22.63 | -17.97 | -109.37 | -195.41 | -192.74 | -86.48 | -88.73 | 0.43 | 1.71 | -7.45 | -12.49 | -11.48 | -11.50 | -10.14 | -8.92 | -8.54 | -7.60 | -6.87 | -4.11 | -4.38 | -3.87 | -2.88 | -2.38 | -1.39 | -1.29 | -2.27 | -0.99 | -0.79 | -0.12 | 1.03 | 0.52 | 0.49 | 3.25 | 3.92 | 6.78 | 7.45 | 4.58 | 3.92 | 1.09 | 0.58 | 1.13 | 1.51 | 2.12 | 2.52 | 2.14 | 1.98 | 1.44 | 1.08 | 1.78 | 1.78 | 2.46 | 2.35 | 2.33 | 2.73 | 2.72 | 3.26 | 0.66 | 0.97 | 0.67 |
Current Ratio |
3.0 | 3.1 | 2.9 | 2.9 | 2.8 | 3.0 | 2.8 | 3.1 | 5.1 | 7.5 | 3.5 | 3.7 | 3.7 | 3.9 | 4.3 | 4.8 | 4.5 | 4.6 | 4.6 | 4.6 | 4.4 | 4.5 | 4.3 | 4.3 | 6.5 | 9.1 | 3.8 | 3.8 | 3.3 | 4.7 | 4.3 | 4.3 | 4.0 | 3.8 | 3.7 | 3.7 | 3.8 | 3.4 | 3.3 | 3.3 | 3.6 | 3.4 | 3.6 | 3.4 | 3.1 | 3.1 | 3.1 | 3.1 | 3.0 | 2.9 | 3.0 | 3.0 | 3.1 | 3.7 | 3.7 | 3.6 | 13.6 | 14.5 | 13.8 | 13.8 |
DSO |
51.3 | 51.5 | - | 54.9 | 51.8 | 56.2 | - | 61.3 | 58.5 | 59.5 | - | 58.6 | 56.9 | 59.2 | 25.7 | 49.4 | 42.9 | 42.0 | 20.8 | 44.2 | 42.1 | 42.1 | 19.9 | 42.7 | 43.4 | 52.6 | 56.8 | 60.1 | 54.5 | 56.8 | 39.3 | 44.3 | 43.9 | 45.8 | 23.6 | 50.5 | 51.4 | 53.3 | 54.2 | 54.9 | 53.9 | 60.4 | 59.8 | 63.8 | 56.7 | 61.8 | 61.4 | 57.7 | 47.0 | 49.2 | 49.1 | 51.8 | 47.7 | 50.4 | 50.1 | 43.8 | 45.4 | 44.7 | 42.5 | - |
DIO |
149.2 | 167.5 | - | 177.6 | 180.9 | 185.8 | - | 141.9 | 146.0 | 136.2 | - | 143.8 | 136.6 | 126.8 | 57.0 | 124.1 | 117.9 | 121.3 | 59.5 | 137.2 | 143.2 | 149.2 | 167.7 | 145.9 | 153.1 | 139.9 | 128.5 | 148.7 | 155.6 | 145.1 | 94.9 | 114.9 | 113.6 | 113.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
75.3 | 87.8 | - | 89.5 | 91.4 | 102.4 | - | 84.5 | 73.4 | 77.1 | - | 79.8 | 72.3 | 66.6 | 28.4 | 59.0 | 56.7 | 52.4 | 24.0 | 49.8 | 42.0 | 43.8 | 53.5 | 49.1 | 55.9 | 65.1 | 73.2 | 69.3 | 56.3 | 53.3 | 34.0 | 41.9 | 40.7 | 36.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
200.5 | 219.0 | - | 232.5 | 232.7 | 242.1 | - | 203.3 | 204.5 | 195.7 | - | 202.4 | 193.4 | 186.0 | 82.7 | 173.4 | 160.8 | 163.3 | 80.3 | 181.4 | 185.4 | 191.3 | 187.7 | 188.5 | 196.4 | 192.5 | 185.3 | 208.8 | 210.0 | 201.8 | 134.2 | 159.2 | 157.4 | 159.4 | 23.6 | 50.5 | 51.4 | 53.3 | 54.2 | 54.9 | 53.9 | 60.4 | 59.8 | 63.8 | 56.7 | 61.8 | 61.4 | 57.7 | 47.0 | 49.2 | 49.1 | 51.8 | 47.7 | 50.4 | 50.1 | 43.8 | 45.4 | 44.7 | 42.5 | - |
Cash Conversion Cycle |
125.2 | 131.2 | - | 143.0 | 141.3 | 139.7 | - | 118.8 | 131.1 | 118.6 | - | 122.7 | 121.1 | 119.4 | 54.3 | 114.4 | 104.1 | 110.9 | 56.3 | 131.7 | 143.4 | 147.5 | 134.2 | 139.4 | 140.6 | 127.4 | 112.1 | 139.5 | 153.7 | 148.6 | 100.2 | 117.3 | 116.7 | 122.7 | 23.6 | 50.5 | 51.4 | 53.3 | 54.2 | 54.9 | 53.9 | 60.4 | 59.8 | 63.8 | 56.7 | 61.8 | 61.4 | 57.7 | 47.0 | 49.2 | 49.1 | 51.8 | 47.7 | 50.4 | 50.1 | 43.8 | 45.4 | 44.7 | 42.5 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company AngioDynamics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 122.35 | 0.73 % | $ 3.92 B | USA |
 |
Alcon
ALC
|
$ 75.8 | -0.08 % | $ 40.4 B |  Schweiz |
 |
Repro Med Systems
KRMD
|
$ 3.96 | -0.75 % | $ 183 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 10.99 | 1.48 % | $ 26.7 M | USA |
 |
The Cooper Companies
COO
|
$ 64.42 | -0.82 % | $ 12.8 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 59.93 | 0.52 % | $ 3.02 B | USA |
 |
electroCore
ECOR
|
$ 6.18 | -0.08 % | $ 52.4 K | USA |
 |
ICU Medical
ICUI
|
$ 124.82 | 0.22 % | $ 3.08 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.8 | -0.89 % | $ 4.5 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
$ 482.22 | 0.71 % | $ 172 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 23.02 | -5.07 % | $ 1.55 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 121.48 | 0.5 % | $ 5.88 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.2 | 0.92 % | $ 101 M |  Israel |
 |
STAAR Surgical Company
STAA
|
$ 25.67 | 3.34 % | $ 1.27 B | USA |
 |
STERIS plc
STE
|
$ 221.8 | -0.77 % | $ 21.9 B | USA |
 |
Masimo Corporation
MASI
|
$ 178.63 | -0.04 % | $ 9.52 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.32 | -1.27 % | $ 26.3 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 10.34 | 0.68 % | $ 214 M | USA |
 |
Stereotaxis
STXS
|
$ 1.93 | -1.53 % | $ 176 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 68.58 | -0.04 % | $ 4.06 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 136.56 | -0.07 % | $ 6.09 B | USA |
 |
Utah Medical Products
UTMD
|
$ 67.17 | -1.03 % | $ 218 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 306.16 | -1.14 % | $ 22.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.91 | 0.08 % | $ 2.37 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.65 | 0.2 % | $ 19.5 M | USA |
 |
Pro-Dex
PDEX
|
$ 52.1 | 2.24 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 113.45 | 0.49 % | $ 2.57 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
$ 21.38 | -1.57 % | $ 985 M | USA |
 |
Baxter International
BAX
|
$ 18.16 | -1.39 % | $ 9.32 B | USA |
 |
ResMed
RMD
|
$ 219.85 | 0.15 % | $ 32.1 B | USA |
 |
AtriCure
ATRC
|
$ 29.28 | 3.79 % | $ 1.4 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 6.86 | 1.18 % | $ 305 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 152.14 | -1.74 % | $ 43.8 B | USA |
 |
Nephros
NEPH
|
$ 2.87 | 1.06 % | $ 29.8 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.0 | -1.64 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
$ 117.6 | 3.1 % | $ 6.55 M | USA |